Targeting Glioblastoma through Nano- and Micro-particle-Mediated Immune Modulation

Ellen Poot; Ander Maguregui; Valerie G. Brunton; Dirk Sieger; Alison N. Hulme

doi:10.1016/j.bmc.2022.116913

Targeting Glioblastoma through Nano- and Micro-particle-Mediated Immune Modulation

Ellen Poot, Ander Maguregui, Valerie G. Brunton, Dirk Sieger, Alison N. Hulme

Research output: Contribution to journal › Article › peer-review

Abstract / Description of output

Glioblastoma Multiforme (GBM) is a multifaceted and complex disease, which has experienced no changes in treatment for nearly two decades and has a 5-year survival rate of only 5.4%. Alongside challenges in delivering chemotherapeutic agents across the blood brain barrier (BBB) to the tumour, the immune microenvironment is also heavily influenced by tumour signalling. Immunosuppression is a major aspect of GBM; however, evidence remains conflicted as to whether pro-inflammatory or anti-inflammatory therapies are the key to improving GBM treatment. To address both of these issues, particle delivery systems can be designed to overcome BBB transport while delivering a wide variety of immune-stimulatory molecules to investigate their effect on GBM. This review explores literature from the past 3 years that combines particle delivery systems alongside immunotherapy for the effective treatment of GBM.

Original language	English
Pages (from-to)	116913
Journal	Bioorganic and Medicinal Chemistry
Early online date	8 Jul 2022
DOIs	https://doi.org/10.1016/j.bmc.2022.116913
Publication status	E-pub ahead of print - 8 Jul 2022

Access to Document

10.1016/j.bmc.2022.116913Licence: CC BY

20220829_Hulme_1-s2.0-S0968089622003066-VoRFinal published version, 7.93 MBLicence: CC BY

https://www.sciencedirect.com/science/article/pii/S0968089622003066

Cite this

@article{981d7642bb94489f99931a3fa1c1d36b,

title = "Targeting Glioblastoma through Nano- and Micro-particle-Mediated Immune Modulation",

abstract = "Glioblastoma Multiforme (GBM) is a multifaceted and complex disease, which has experienced no changes in treatment for nearly two decades and has a 5-year survival rate of only 5.4%. Alongside challenges in delivering chemotherapeutic agents across the blood brain barrier (BBB) to the tumour, the immune microenvironment is also heavily influenced by tumour signalling. Immunosuppression is a major aspect of GBM; however, evidence remains conflicted as to whether pro-inflammatory or anti-inflammatory therapies are the key to improving GBM treatment. To address both of these issues, particle delivery systems can be designed to overcome BBB transport while delivering a wide variety of immune-stimulatory molecules to investigate their effect on GBM. This review explores literature from the past 3 years that combines particle delivery systems alongside immunotherapy for the effective treatment of GBM.",

author = "Ellen Poot and Ander Maguregui and Brunton, {Valerie G.} and Dirk Sieger and Hulme, {Alison N.}",

note = "Funding Information: We thank the BBSRC (EASTBIO DTP Studentship to EP; Grant Ref BB/T00875X/1) and EPSRC (DTA Studentship to AM; Grant Ref EP/R513209/1) for funding. For the purpose of open access, the author has applied a Creative Commons Attribution (CC BY) licence to any Author Accepted Manuscript version arising from this submission. Publisher Copyright: {\textcopyright} 2022 The Author(s)",

year = "2022",

month = jul,

day = "8",

doi = "10.1016/j.bmc.2022.116913",

language = "English",

pages = "116913",

journal = "Bioorganic and Medicinal Chemistry",

issn = "0968-0896",

publisher = "Elsevier",

}

TY - JOUR

T1 - Targeting Glioblastoma through Nano- and Micro-particle-Mediated Immune Modulation

AU - Poot, Ellen

AU - Maguregui, Ander

AU - Brunton, Valerie G.

AU - Sieger, Dirk

AU - Hulme, Alison N.

N1 - Funding Information: We thank the BBSRC (EASTBIO DTP Studentship to EP; Grant Ref BB/T00875X/1) and EPSRC (DTA Studentship to AM; Grant Ref EP/R513209/1) for funding. For the purpose of open access, the author has applied a Creative Commons Attribution (CC BY) licence to any Author Accepted Manuscript version arising from this submission. Publisher Copyright: © 2022 The Author(s)

PY - 2022/7/8

Y1 - 2022/7/8

N2 - Glioblastoma Multiforme (GBM) is a multifaceted and complex disease, which has experienced no changes in treatment for nearly two decades and has a 5-year survival rate of only 5.4%. Alongside challenges in delivering chemotherapeutic agents across the blood brain barrier (BBB) to the tumour, the immune microenvironment is also heavily influenced by tumour signalling. Immunosuppression is a major aspect of GBM; however, evidence remains conflicted as to whether pro-inflammatory or anti-inflammatory therapies are the key to improving GBM treatment. To address both of these issues, particle delivery systems can be designed to overcome BBB transport while delivering a wide variety of immune-stimulatory molecules to investigate their effect on GBM. This review explores literature from the past 3 years that combines particle delivery systems alongside immunotherapy for the effective treatment of GBM.

AB - Glioblastoma Multiforme (GBM) is a multifaceted and complex disease, which has experienced no changes in treatment for nearly two decades and has a 5-year survival rate of only 5.4%. Alongside challenges in delivering chemotherapeutic agents across the blood brain barrier (BBB) to the tumour, the immune microenvironment is also heavily influenced by tumour signalling. Immunosuppression is a major aspect of GBM; however, evidence remains conflicted as to whether pro-inflammatory or anti-inflammatory therapies are the key to improving GBM treatment. To address both of these issues, particle delivery systems can be designed to overcome BBB transport while delivering a wide variety of immune-stimulatory molecules to investigate their effect on GBM. This review explores literature from the past 3 years that combines particle delivery systems alongside immunotherapy for the effective treatment of GBM.

U2 - 10.1016/j.bmc.2022.116913

DO - 10.1016/j.bmc.2022.116913

M3 - Article

SN - 0968-0896

SP - 116913

JO - Bioorganic and Medicinal Chemistry

JF - Bioorganic and Medicinal Chemistry

ER -

Targeting Glioblastoma through Nano- and Micro-particle-Mediated Immune Modulation

Abstract / Description of output

Access to Document

Fingerprint

Cite this